---
title: "UltraGreen.ai invests $12.3m in LifeSignals, IHLD"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286977584.md"
description: "UltraGreen.ai has invested $12.3m from its IPO proceeds in LifeSignals and IHLD Med Tech to support strategic growth initiatives. The investment includes $5.8m for LifeSignals to enhance biosensor manufacturing and $3.8m for IHLD to expand its platform in India. These transactions are not expected to materially impact FY2026 EPS. UltraGreen.ai retains a balance of $171.8m from its IPO proceeds, aligning with its prospectus intentions."
datetime: "2026-05-19T23:42:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286977584.md)
  - [en](https://longbridge.com/en/news/286977584.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286977584.md)
---

# UltraGreen.ai invests $12.3m in LifeSignals, IHLD

**The investments were funded from IPO proceeds and are not expected to materially affect FY2026 EPS.**

UltraGreen.ai has used $12.3m (US$7.5m) of its initial public offering proceeds for convertible loans to LifeSignals Group and IHLD Med Tech as part of its strategic growth initiatives.

The company invested $5.8m (US$4.5m) in LifeSignals to support biosensor manufacturing, software enhancements, and working capital requirements.

LifeSignals’ biosensors are distributed internationally through UltraGreen.ai’s subsidiary, UltraGreen Data Systems.

The collaboration will support commercialisation under a new brand, UltraGreen Cardiac Technologies, which will represent the group’s cardiology distribution business.

UltraGreen.ai said the partnership is expected to contribute revenue through the sale and distribution of LifeSignals Holter devices, with an initial focus on the US and Europe.

LifeSignals is an associate of Renew Group, a controlling shareholder of UltraGreen.ai. The investment is therefore an interested person transaction, but does not require shareholders’ approval as it does not reach the relevant threshold under Chapter 9 of the Listing Manual.

UltraGreen.ai also invested $3.8m (US$3m) in IHLD Med Tech through a convertible loan to expand its fluorescence-guided platform into India’s wound care market. The investment may increase to up to $15.4m (US$12m), subject to agreed milestones.

The IHLD initiative will initially focus on wound care across cardiac, diabetic, trauma, and other clinical applications. Go-to-market activities are expected to begin in the next two to three months.

UltraGreen.ai said the LifeSignals and IHLD transactions are not expected to have any material impact on the group’s earnings per share for the financial year ending 31 December 2026.

Including $1.9m (US$1.5m) used for working capital and general corporate purposes, UltraGreen.ai has used $11.5m (US$9.0m) of its IPO proceeds, leaving a balance of $171.8m (US$134.1m). The company said the utilisation is in line with the intended use set out in its prospectus.

($1 = US$0.78)

### Related Stocks

- [ULG.SG](https://longbridge.com/en/quote/ULG.SG.md)

## Related News & Research

- [UltraGreen.ai Limited (ULG) Gets a Buy from UOB Kay Hian](https://longbridge.com/en/news/285415825.md)
- [AI face is taking over — and driving plastic surgeons crazy](https://longbridge.com/en/news/286641783.md)
- [Cathie Wood Snatches Up $46.4 Million of the Hottest AI IPO of the Year. Here’s Why.](https://longbridge.com/en/news/286795261.md)
- [06:07 ETStandardC Launches AI Platform for Financial Institutions, Where Customer PII Is Never Shared With AI Models (Patent Pending)](https://longbridge.com/en/news/286892045.md)
- [11:30 ETDageno Launches Issues Panel and High-volume Prompt Miner to Help Growing Brands Turn AI Search Signals Into Growth Tasks](https://longbridge.com/en/news/286939643.md)